# Low Dose Rosuvastatin Plus Ezetimibe Versus High-dose Rosuvastatin in AMI

> **NCT04499859** · PHASE4 · RECRUITING · sponsor: **Kiyuk Chang, MD,PhD** · enrollment: 3548 (estimated)

## Conditions studied

- Myocardial Infarction
- Statin Adverse Reaction
- HMG-CoA Reductase Inhibitor Toxicity

## Interventions

- **DRUG:** Ezetimibe 10mg + Rosuvastatin 5mg
- **DRUG:** Rosuvastatin 20mg

## Key facts

- **NCT ID:** NCT04499859
- **Lead sponsor:** Kiyuk Chang, MD,PhD
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-10-01
- **Primary completion:** 2026-08-30
- **Final completion:** 2027-08-30
- **Target enrollment:** 3548 (ESTIMATED)
- **Last updated:** 2025-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04499859

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04499859, "Low Dose Rosuvastatin Plus Ezetimibe Versus High-dose Rosuvastatin in AMI". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04499859. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*